From NYT - Questioning a Cancer Drug That Costs $30,000 a Month | DNDNQ Message Board Posts

Dendreon Corporation

  DNDNQ website

DNDNQ   /  Message Board  /  Read Message

 

 






Keyword
Subject
Between
and
Rec'd By
Authored By
Minimum Recs
  
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board
Msg  315371 of 486901  at  12/5/2009 5:23:17 AM  by

foolishpetey


 In response to msg 315370 by  steveporsche
view thread

Re: From NYT - Questioning a Cancer Drug That Costs $30,000 a Month

"Folotyn has not yet shown an effect on longevity. In the clinical trial that led to approval of the drug, 27 percent of the 109 patients experienced a reduction in tumor size. The reductions lasted a median of 9.4 months.

But considering all the patients in the trial, only 12 percent had a reduction in tumor size that lasted for more than 14 weeks. The trial did not compare Folotyn to another drug or a placebo."

WOW!!! Talk about backasswards.

fda had better approve Provenge.


     e-mail to a friend      printer-friendly     add to library      
| More
Recs: 15     Views: 332
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board

Replies
Msg # Subject Author Recs Date Posted
315381 Re: From NYT - Questioning a Cancer Drug That Costs $30,000 a Month DNDN_BULL 2 12/5/2009 9:35:15 AM






About Us  •  Contact Us  •  Follow Us on Twitter  •  Members Directory  •  Help Center  •  Advertise
Not a member yet? What are you waiting for? Create Account
Want to contribute? Support InvestorVillage by donating
© 2003-2019 Investorvillage.com. All rights reserved. User Agreement
   
Financial Market Data provided by
.


Loading...